Director Patrick Enright awarded 17,084 Vera Therapeutics (VERA) stock options

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Vera Therapeutics director Patrick G. Enright received a stock option grant for 17,084 shares of Class A common stock. The option has an exercise price of $34.35 per share and expires on May 20, 2036. All 17,084 options were held directly after the grant.

The footnote states the option will vest in full on the earlier of the first anniversary of the grant date or the date of Vera Therapeutics' 2027 annual stockholder meeting, subject to continuous service. It will also vest in full upon a change in control if his service continues through that date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider ENRIGHT PATRICK G

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	17,084	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 17,084 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Option shares granted: 17,084 shares Exercise price: $34.35 per share Shares underlying options: 17,084 shares +2 more

5 metrics

Option shares granted 17,084 shares Stock option grant to director Patrick G. Enright

Exercise price $34.35 per share Strike price for the granted stock options

Shares underlying options 17,084 shares Class A common stock underlying the option

Expiration date May 20, 2036 Option expiration for the grant

Post-grant option holdings 17,084 derivative securities Total options held following the transaction

Key Terms

Stock Option (right to buy), Class A Common Stock, exercise price, change in control, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Class A Common Stock financial

"underlying_security_title: Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

exercise price financial

"conversion_or_exercise_price: 34.3500"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

change in control financial

"shares will vest in full upon a change in control"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

continuous service financial

"subject to the Reporting Person's continuous service through such vesting date"

Form 4 Insider Transactions: What Each Field Means →

05/26/2026 - 04:15 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ENRIGHT PATRICK G

(Last)

(First)

(Middle)

C/O LONGITUDE CAPITAL MANAGEMENT

2740 SAND HILL ROAD, 2ND FLOOR

(Street)

MENLO PARK

CALIFORNIA

94025

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vera Therapeutics, Inc. [ VERA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$34.35	05/21/2026		A		17,084		⁽¹⁾	05/20/2036	Class A Common Stock	17,084	$0	17,084	D

Explanation of Responses:

1. The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control.

	/s/ Joseph R. Young, Attorney-in-Fact	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Patrick G. Enright report in this Vera Therapeutics (VERA) Form 4?

Patrick G. Enright reported receiving a grant of stock options for 17,084 shares of Vera Therapeutics Class A common stock. The options are a compensation-related award, not an open-market purchase or sale, and are held directly following the transaction.

What is the exercise price of the Vera Therapeutics (VERA) options granted to Patrick G. Enright?

The stock options granted to Patrick G. Enright have an exercise price of $34.35 per share. This means he can purchase Vera Therapeutics Class A common stock at $34.35 per share once the options vest, subject to the vesting conditions described.

How many Vera Therapeutics (VERA) shares are covered by Patrick G. Enright’s option grant?

The option grant covers 17,084 shares of Vera Therapeutics Class A common stock. After this grant, Enright held options for all 17,084 underlying shares directly, according to the post-transaction holdings disclosed in the Form 4 filing.

When do Patrick G. Enright’s Vera Therapeutics (VERA) options vest?

The options vest in full on the earlier of the first anniversary of the grant date or Vera Therapeutics’ 2027 annual stockholder meeting. Vesting requires Patrick G. Enright’s continuous service, with full vesting also triggered upon a change in control if he remains in service.

When do Patrick G. Enright’s Vera Therapeutics (VERA) stock options expire?

The stock options granted to Patrick G. Enright expire on May 20, 2036. If not exercised by that expiration date, the right to purchase Vera Therapeutics Class A common stock at the $34.35 exercise price will lapse under the terms disclosed.

Is Patrick G. Enright’s Vera Therapeutics (VERA) Form 4 transaction a market buy or sell?

The filing shows a grant or award acquisition of stock options, not a market buy or sell. The transaction code is “A,” indicating a compensation-related award with no open-market purchase or sale of Vera Therapeutics common shares.